Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.
The drug is used to treat advanced or recurrent metastatic colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy.
Shares of Hutchmed closed nearly 3% higher on Tuesday.
Price (HKD): $26.65, Change: $+0.75, Percent Change: +2.90%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments